EUVIMEDEUVIMED entdecken
Open Access

Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer

Zhaojun Qiu, Deepika Sigh, Yujie Liu, Chandra B Prasad, Nichalos Bean, Chunhong Yan, Zaibo Li, Xiaoli Zhang, Goutham Narla, Analisa DiFeo, Qi-En Wang, Junran Zhang

Theranostics · 2024

DOI: 10.7150/thno.96879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Zhaojun Qiu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio-43210, United States. Hauptthemen laut MEDLINE: Protein Phosphatase 2, Checkpoint Kinase 1, Ovarian Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

High-grade serous ovarian cancer (HGSOC), the most lethal epithelial ovarian cancer subtype, faces persistent challenges despite advances in the therapeutic use of PARP inhibitors. Thus, innovative strategies are urgently needed to improve survival rates for this deadly disease. Checkpoint kinase 1 (CHK1) is pivotal in regulating cell survival during oncogene-induced replication stress (RS). While CHK1 inhibitors (CHK1i's) show promise as monotherapy for ovarian cancer, a crucial biomarker for effective stratification in clinical trials is lacking, hindering efficacy improvement and toxicity reduction. PP2A B55α, encoded by PPP2R2A, is a regulatory subunit of the serine/threonine protein phosphatase 2 (PP2A) that influences CHK1 sensitivity in non-small cell lung cancer (NSCLC). Given the complexity of PP2A B55α function in different types of cancer, here we sought to identify whether PPP2R2A deficiency enhances the sensitivity of HGSOC to CHK1 inhibition.

Methods

To determine whether PPP2R2A deficiency affects the sensitivity of HGSOC to CHK1 inhibition, we treated PPP2R2A knockdown (KD) HGSOC cells or HGSOC cells with naturally low PPP2R2A expression with a CHK1 inhibitor, then assessed cell growth in in vitro and in vivo assays. Additionally, we investigated the mechanisms contributing to the increased RS and the enhanced sensitivity to the CHK1 inhibitor in PPP2R2A-KD or deficient cells using various molecular biology assays, including western blotting, immunofluorescence, and DNA fiber assays.

Results

Our study suggests that PPP2R2A-KD elevates c-Myc-induced RS via upregulation of replication initiation, rendering HGSOC cells reliant on CHK1 for survival, including those resistant to PARP inhibitors.

Conclusion

Combined, these results identify PPP2R2A/PP2A B55α as a potential predictive biomarker for CHK1i sensitivity in HGSOC, as well as suggesting it as a therapeutic target to overcome PARP resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Phosphatase 2Checkpoint Kinase 1Ovarian NeoplasmsHumansFemaleCell Line, TumorAnimalsMiceProtein Kinase InhibitorsCystadenocarcinoma, SerousXenograft Model Antitumor Assays

Substanzen

Protein Phosphatase 2Checkpoint Kinase 1PPP2R2A protein, humanCHEK1 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio-43210, United States.
  • Georgia Cancer Center, Augusta University Medical College, 1410 Laney Walker Blvd., CN-2134, Augusta, Georgia-30912, United States.
  • Department of Pathology, The Ohio State University Wexner Medical Center, College of Medicine, Columbus, Ohio-43210, United States.
  • Department of Biomedical Informatics, Wexner Medical Center, College of Medicine, The Ohio State University, Ohio-43210, United States.
  • Department of Internal Medicine, University of Michigan, Ann Arbor, MI-48109, United States.
  • The James Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio-43210, United States.

Förderung

  • NCI NIH HHS

Zitieren

APA

Qiu, Z., Sigh, D., Liu, Y., Prasad, C. B., Bean, N., Yan, C., Li, Z., Zhang, X., Narla, G., DiFeo, A., Wang, Q. E., & Zhang, J. (2024). Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. Theranostics. https://doi.org/10.7150/thno.96879

Vancouver

Qiu Z, Sigh D, Liu Y, Prasad CB, Bean N, Yan C, et al. Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. Theranostics. 2024. doi:10.7150/thno.96879

BibTeX
@article{Qiu2024,
  author = {Qiu, Zhaojun and Sigh, Deepika and Liu, Yujie and Prasad, Chandra B and Bean, Nichalos and Yan, Chunhong and Li, Zaibo and Zhang, Xiaoli and Narla, Goutham and DiFeo, Analisa and Wang, Qi-En and Zhang, Junran},
  title = {Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer},
  journal = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.96879}
}
Kostenlos starten →